Mechanistical retinal drug targets and challenges

Area of Science:

• Ophthalmology and visual sciences.
• Neuroscience and neurodegenerative diseases.
• Pharmacology and drug discovery.

Background:

• Retinal cells face constant light-induced oxidative stress.
• Oxidative stress, inflammation, and neurodegeneration drive major retinal diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR).
• Current treatments offer limited efficacy for many retinal conditions.

Purpose of the Study:

• To review promising mechanistic drug targets for retinal diseases.
• To explore novel therapeutic strategies and drug delivery systems for the posterior segment of the eye.
• To focus on targets beyond vascular endothelial growth factor (VEGF) signaling and anti-VEGF therapies.

Main Methods:

• Literature review of recent research on retinal drug targets.
• Analysis of mechanistic pathways involved in retinal diseases.
• Discussion of emerging therapeutic approaches and drug delivery innovations.

Main Results:

• Identification of several promising mechanistic drug targets for retinal diseases.
• Exploration of novel therapeutic strategies beyond anti-VEGF treatments.
• Highlighting advancements in drug delivery to the posterior eye segment.

Conclusions:

• Novel drug targets and advanced delivery methods offer a promising future for treating retinal diseases.
• Targeting underlying mechanisms of oxidative stress, inflammation, and neurodegeneration is crucial.
• Further research into these targets could lead to effective treatments for both common and rare retinal conditions.